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Discussion & Conclusions

Case Description & Results

 Charcot-Marie-Tooth (CMT) is a phenotypically and genetically heterogenous group of
inherited peripheral neuropathies. With a prevalence of 1:2500, it is the most common
hereditary neurologic condition.[1-4]
 CMT typically manifests as chronic, length-dependent motor and sensory loss resulting
from demyelination (CMT1) or axonal loss (CMT2). Onset and severity are widely
variable, even amongst individuals with identical mutations.[1-4,13-15,19-22]
 Next-generation sequencing (NGS) has facilitated rapid CMT gene discovery in recent
years. To date, >100 CMT-causative genes are reported, with substantial allelic and locus
heterogeneity observed.[5-10]
 Mutations in the mitofusin-2 (MFN2) gene cause axonal CMT (CMT2A), typically
dominantly-inherited missense mutations.[1,2,11-16] Additional MFN2-associated
symptoms are common,[10] including: optic atrophy,[17-20] autonomic dysfunction,[20-21]
diaphragm/respiratory dysfunction,[20] neuropathic pain.[10,25]
 MFN2, a mitochondrial membrane GTPase, is essential for mitochondrial dynamics and
trafficking. It is critically involved in axonal transport. [11-16, 22-25]
 Today, NGS is employed clinically through targeted multigene panels. Panels are a
sensitive, efficient tool for establishing definitive molecular CMT diagnosis, with
diagnostic yields approaching 70% in some cohorts.[5-10]

Case Description & Results
We present a case of a 55-year-old man with chronic length-dependent
sensory changes, autonomic symptoms, and a positive family history.
Initial evaluation (age 52). Presented with painful parasthesias in bilateral feet and
occasional orthostatic lightheadedness. Examination revealed decreased sensation
below the ankles bilaterally with preserved strength and reflexes. NCS/EMG
demonstrated mild, symmetric axonal sensorimotor polyneuropathy consistent with
CMT2 (Table 1). Autonomic function testing was abnormal, suggesting axonal small
fiber neuropathy and dysautonomia. Laboratory evaluation was unremarkable.
Re-evaluation (age 55). Presented with worsening neuropathic and orthostatic
symptoms. He reported severe orthostatic hypotension and exertional syncope.
He endorsed subacute visual changes. Examination and NCS/EMG
confirmed progression of axonal polyneuropathy. Further family history
revealed similar symptoms in his mother (IB) and sister (IIB). Inherited neuropathy
was suspected.
Table 1. Nerve Conduction Studies (NCS) of
proband (IIA) at age 55. Sensory NCS (top)
and Motor NCS (bottom). Results suggest
neuropathy progression with reduced (red
font) or absent sensory amplitudes, and
normal-range CMAP amplitudes that were
decreased from prior study (at age 52). LE =
Lower Extremity, Lat. = Latency (for sensory
studies, onset latency is used), Amp. =
Amplitude, SCV = Sensory Conduction
Velocity, MCV = Motor Conduction
Velocity, EDB = Extensor Digitorum Brevis
muscle, AH = Abductor Hallicus muscle, A =
Ankle, FH = Fibular Head, PF = Popliteal
Fossa.

Targeted gene sequencing of the proband (IIA) was obtained using the 72-gene
Comprehensive Neuropathies Panel through Invitae commercial laboratories (San
Francisco, CA). Results returned heterozygous variants of uncertain significance
(VUS) in 3 genes: KIF1A (c.3584G>A; p.Arg1195His), MFN2 (c.1979C>A;
p.Ala660Asp), PLEKHG5 (c.823G>A; pGly275Ser).
Confirmatory familial testing revealed all 3 variants in his mother (IB), and MFN2
and PLEKHG5 variants in his sister (IIB). Both individuals had electrodiagnosticallyconfirmed axonal polyneuropathy and reported additional symptoms
(Table 2). MFN2-related disease was suspected in this family.

Figure 1. Family pedigree
with summarized variant
findings. Proband (IIA) is
indicated by blue arrow.
Shaded shapes represent
symptomatic individuals.
Pattern
suggests likely
autosomal
dominant
inheritance. m = mutated
allele, wt = wild type
(normal) allele.

Table 2. Clinical features of proband (IIA) and symptomatic family members (IB,
IIB). In all 3 individuals, sensorimotor symptoms were the presenting symptoms at onset.
In patients IIA and IIB, autonomic symptoms began in 5th decade of life and were
confirmed with quantitative autonomic function testing. LL = Lower Limb

We describe the case of a 55-year-old man (proband, IIA) with
axonal polyneuropathy, associated autonomic and visual symptoms, and a
family history of the same symptoms. Clinical and genomic evaluation of
the proband and 2 relatives (IB, IIB) suggests that the shared variant
in MFN2 (c.1979C>A; p.Ala660Asp) is the most likely punitive mutation in
this family.
 All 3 patients had electrodiagnostic and clinical features of lengthdependent axonal polyneuropathy (CMT2). All developed symptoms in
adulthood, although onset ranged from 4th decade (IIA, IIB) to 6th
decade (IB) of life. All had additional symptoms, which were consistent
with those commonly reported in MFN2-related disease - neuropathic
pain and visual symptoms (IIA, IB, IIB), autonomic dysfunction (IIA, IIB),
diaphragm weakness with respiratory difficulty (IB) - although severity
was variable between family members. Pedigree suggests autosomal
dominant inheritance.
 The identified MFN2 sequence variant yields a dominantly-inherited
missense mutation, resulting in an amino acid substitution between Cterminal TM2 and HR2 domains. This alteration disrupts physiologic
MFN2 protein function according to Invitae's in silico functional
protein modeling. This mutation is located far from the highlyconserved GTPase domain; such C-terminal (non-GTPase) mutations
are associated with adult-onset, non-severe disease and phenotypic
heterogeneity, consistent with this family's phenotype. [21-25]
 The other variant shared by all 3 patients, in PLEKHG5, is unlikely to be
the culprit given its typical autosomal recessive inheritance pattern.
Despite an established link between MFN2 mutations and CMT2A, the
molecular mechanisms by which MFN2 mutations lead to disease are
largely unknown. This is likely due to the complex, multifunctional role of
MFN2 in neurons. [11,14]
Targeted multigene panels have allowed for efficient, detailed genomic
investigation in CMT patients. When VUS result, interpretation is
challenging. Confirmatory family studies can help to clarify variant
pathogenicity. [5-10]
The genetic and clinical data in this report help to broaden the spectrum of
MFN2-related disease and strengthrn genotype-phenotype correlations in
CMT. This understanding can improve genetic counseling of patients and
support future disease-focused therapies. [22,23]

Figure 2. Schematic representation of MFN2 protein structure. MFN2 is a 757 AA protein with 4 major functional domains: 1 GTPase domain, 2 Heptad Repeat (HR) coiled-coil
domains, and 2 transmembrane (TM) domains. The GTPase and HR2 domains interact to execute GTP hydrolysis during mitochondrial fusion; pathogenic MFN2 mutations are
most commonly located in these domains (noted by star). GTPase mutations result in severe, childhood-onset CMT2A. Non-GTPase mutations are associated with less severe,
adult-onset CMT2A with broad phenotypic heterogeneity.[14,15,21-24] The...

